Summary. Five pregnant beagle bitches were treated with 2\ m=. \ 5mg mifepristone/kg body weight, twice a day, for 4\m=.\5 days starting at Day 32 of gestation. Results of fetal ultrasonography and assay of serum progesterone concentrations every 2\p=n-\4 days were compared to those in 5 control bitches. Mifepristone resulted in a premature (P < 0\m=.\01) termination of pregnancy (36 \m=+-\ 1vs 65 \m=+-\1 days), without side effects. The antiprogestagen also caused progesterone to decline to < 1 ng/ml by Day 40\p=n-\45 after the preovulatory LH peak (vs 64\p=n-\67days in controls) and reduced (P < 0\m=.\05) mean concentrations on Days 34\p=n-\50 (2\m=.\2\ m=+-\ 0\m=.\5vs 6\m=.\3\ m=+-\0\m=.\3 ng/ml). The results suggest that antiprogestagen therapy is a safe means to terminate unwanted pregnancy in dogs, and that luteal function in pregnant bitches is dependent on luteotrophic support that is blocked by antiprogestagen treatment, directly or indirectly, due to termination of pregnancy.
Introduction
Methods for post-coital contraception and induction of abortion in dogs are needed to prevent the birth of unwanted litters that result from unplanned matings. However, safe and efficacious methods are not readily available and oestrogen administration to prevent implantation can have particularly harmful effects (Concannon, 1983; Bowen et ai, 1985) . Pregnancy in the bitch is depen¬ dent on ovarian progesterone secretion throughout gestation (Sokolowski, 1974; Concannon et ai, 1977) and both LH and prolactin are required luteotrophins (Concannon et ai, 1987) . Pregnancy can be terminated by luteolytic treatments, including repeated administration of prostaglandin F-2a Paradis et ai, 1983) or of prolactin-lowering doses of bromocriptine (Concannon, 1986) . Both treatments produce various undesirable side effects and neither is approved for use in dogs. The potential to terminate pregnancy in dogs by administration of an antiprogestagen has not been reported. Mifepristone, a 19-norsteroid [I7ß-hydroxy-l lß-(4-dimethylamino-phenyl)-17a-(l-propynyl)-oestra-4,9-diene-3-one: Roussel-Uclaf, Paris, France] is a progesterone and glucocorticoid receptor antagonist. Its antiprogestagenic activity has been demonstrated in rodents and rabbits (Philibert et ai, 1982) , monkeys (Koering et ai, 1986) and dogs (Concannon et ai, 1988a) . Anticorticoid activity has been demonstrated in rodents (JungTestas & Baulieu, 1983) , man (Gaillard et ai, 1985) and dogs (Spitz et ai, 1985) . Mifepristone has been reported to terminate pregnancy in monkeys (Hodgen, 1985) and women (Kovacs et ai, 1984; Couzinet et ai, 1986) . Administration of this antiprogestagen can also cause premature luteolysis in non-pregnant women (Nieman et ai, 1987) . The present study was conducted to determine the effects of low doses of mifepristone on pregnancy maintenance in dogs and potential concomitant effects on luteal function.
The bitches were 2-6-year-old beagles maintained indoors and monitored for pro-oestrus and oestrus as previously described (Concannon et ai, 1977 (Concannon et ai, , 1987 (Concannon & DiGregorio, 1986) . The day of the preovulatory LH surge was considered to be the first day which was 7-9 days before the late-oestrous change in the vaginal smear and also within 1 day of the first elevation in progesterone above 1 ng/ml which was followed by a persistent rise in progesterone.
Pregnancy Srikandakumar et al. (1986) for dog plasma and used in our laboratory (Concannon, 1989) . In brief, 100 µ samples of dog serum, or standard progesterone in human serum were incubated in antibody-coated tubes along with 125I-labelled progesterone for 3 h at 22°C. The entire volume was aspirated, and radioactivity in the tubes was counted. Each assay also included aliquants of 2 serum pools which had been previously assayed for progesterone content using extraction, monitoring of recovery, antiserum of high specificity, and validated double-antibody radioimmunoassay procedures previously described in detail (Concannon el ai, 1983; Reimers el ai, 1983) . The sensitivity was 01 ng/ml. Mean within-assay coefficients of variation ranged from 4 to 7% and averaged 6%. Between-assay coefficients of variation for 2 pools of serum containing 4 and 15 ng/ml were 8% and 6%, respectively, in 8 assays.
Results
The number of individual fetuses that could be distinguished and monitored by ultrasound varied within individual bitches and ranged from 4 to 7. However, the actual numbers may have been greater. The effects of mifepristone treatment starting at Day 32 are summarized and compared to observations in control pregnancies in Fig. 1 . The absence of fetal heart movements in individual fetuses was first observed at 2-3-5 days after start of treatment. Complete termination of preg¬ nancy, defined as the death of all fetuses, occurred 3-5-4-5 days after start of treatment on Day 32. However, in the bitch for which treatment started on Day 22 of pregnancy, the last fetus but one died after 6-5 days, and the remaining fetus died at 15 days after start of treatment (see Fig. 2 (Fig. 1) . The mean serum concentrations of progesterone after treatment ranged from 1-3 to 4-9 ng/ml in bitches treated with mifepristone from Day 32, and from 4-2 to 9-2 ng/ml in controls. Mean progesterone values in bitches administered mifepristone (2-2 + 0-5 ng/ml) were lower (P < 005) than in controls (6-3 ± 0-3 ng/ml).
The results suggest that oral antiprogestagen therapy can be used as a safe and effective method for the termination of unwanted pregnancy in dogs. The rapid termination of pregnancy by mifepris¬ tone treatment is consistent with the reported progesterone-antagonist effects of this steroid in several species, including dogs (Concannon et ai, 1988a) , monkeys (Healy et ai, 1983; Koering et ai, 1986) and humans (Schaison et ai, 1985) , and the ability of mifepristone to terminate pregnancy in women (Kovacse/a/., 1984; Couzinet et ai, 1986) . The fact that the termination of all pregnancies occurred in the presence of elevated concentrations of progesterone demonstrates that the abortifacient effect was due to direct progesterone antagonist effects at the level of the uterus and independent of any additional effects on luteal function.
The premature cessation of luteal function in antiprogestagen-treated animals may have occurred secondary to the termination of pregnancy or may represent a luteolytic effect of treat¬ ment independent of pregnancy status. There is some evidence that pregnancy in dogs promotes greater luteal activity and progesterone secretion than that observed in non-pregnant dogs at a comparable time in the luteal phase (Smith & McDonald, 1974; Concannon et ai, 1977) . Perhaps some pregnancy-specific luteotrophic activity was withdrawn by termination of pregnancy in these bitches. Luteolysis secondary to abortions or résorptions could be related to a uterine release of luteolytic amounts of prostaglandin F-2a such as normally occurs at parturition (Concannon et ai, 1988b) . Mifepristone can induce endometrial prostaglandin secretion in vitro (Kelly et ai, 1985) . A pituitary effect could also be involved, since mifepristone has antigonadotrophic activity in non¬ pregnant women (Schaison et ai, 1985) . Finally, a direct ovarian effect cannot be dismissed. Mifepristone suppresses 3ß-hydroxysteroid dehydrogenase and 17-hydroxylase activities of human ovarian tissue in vitro (DiMattina et ai, 1987) .
A longer period of treatment with mifepristone was required to compromise most of the fetuses when started at Day 22, when serum progesterone concentration at the start of treatment was higher than in bitches treated later in pregnancy. This suggests that the 5 mg/kg dose of mife¬ pristone may have been near the lower end of the effective range, and that abortifacient efficacy may be dependent on the serum concentrations of progesterone present during treatment. Such a conclusion would be in agreement with the fact that the 5 mg/kg dose antagonized only about 60% of the uterine stimulation caused by physiological doses of progesterone in oestrogenprimed immature bitches (Concannon et ai, 1988a) . In contrast, a dose of 20 mg/kg antagonized over 80% of the activity of the exogenous progesterone. Oral antiprogestagenic activity of mife¬ pristone in dogs may be lower than in humans, since in women a single dose of 10 mg/kg consis¬ tently induced menses during the mid-luteal phase when plasma progesterone concentrations were 8-34 ng/ml.
Since no adverse side effects were noted, increasing the dosage to 10 mg/kg/day might be an appropriate means to increase abortifacient efficacy during early pregnancy. In humans, aborti¬ facient efficacy had no apparent dose dependency in a study with a narrow dose range (Couzinet et ai, 1986) , but the luteolytic effect did appear to be dose-dependent (Nieman et ai, 1987) . The latter may be true in dogs. Parenteral doses of 2 mg/kg at 2-3-day intervals reduced the extent of clinical pseudopregnancy in bitches but did not significantly shorten the lifespan of the corpus luteum (Gerres et ai, 1988) . Although mifepristone has anticorticoid activity in dogs (Spitz et ai, 1985) , anticorticoid activity was limited to doses of 20 or 50 mg/kg and not observed with the 5 mg/kg dose, as used in the present study. In conclusion, administration of an antiprogestagen such as mifepristone terminates pregnancy in dogs; the resulting luteolysis suggests a possible luteal dependence on feto-placental integrity and/or a delayed sensitivity to pituitary, uterine or ovarian effects of antiprogestagen therapy.
